Clubhouse logo

Dr. Reiersen




🗣Reiersen = “RAY-er-sen” 🧠Psychiatrist ➡️ 🦠COVID scientist💊🩺 ********📰LATEST NEWS📰******** *SJCAPP paper on psychiatric diagnoses and medications in Wolfram Syndrome: *We are recruiting long haulers in Missouri & Illinois for our Fluvoxamine LONG COVID TRIAL. See flyer on my Instagram, FB, or X (formerly twitter) account . ************************************* 🥼Co-PI, “STOP COVID” trials: 💊fluvoxamine vs placebo for prevention of 🫁respiratory deterioration in outpatients 🦠with COVID19 (OFF-LABEL USE) 💊fluvoxamine LONG COVID trial is now IN PROGRESS. ℹ️👨‍⚕️👩🏽‍💻💁🏻‍♀️👨🏾‍⚕️🧑🏿‍⚕️ HEALTHY MIND LAB: 🌐 🩺👩🏽‍⚕️A good review paper: 📙Facente SN, et al., 2021 📚PMID: 34851510 🎥 Includes video abstract❣️ 📰💊Fluvoxamine (FLV) COVID19 News: 📈 Together Trial (Brazil) FLV results: 💠~32% ⬇️ hospitalization risk! For those taking 80% of pills: 💠~66% ⬇️ hospitalization risk! 💠~91% ⬇️ mortality risk! 📄LANCET GLOBAL HEALTH 10/27/21📚PMID: 34717820 📓STOP COVID 1 results: 🌐 📓Article on fluvoxamine mechanisms in COVID19: 🌐 📓STOP COVID 2 results: 🌐 📰📰 NEWS articles about 📰📰 📰STOP COVID 1 & STOP COVID 2📰 (Search: source + fluvoxamine + COVID) 🗞LA TImes (Lopez) 🗞Washington Post (Klausner) 🗞Health Affairs Blog (Sukhatme & Sukhatme) 🗞Scientific American (Schmidt) 🗞CNN (Cohen, Gupta & Kane) 🗞Cerebrum (Reiersen) 📺⏱CBS/60Minutes (3/7/21)⏱ 📔Relevant research article PMIDs📔 (Search PubMed for these PMIDs) 📚33180097📚32271506📚33403480 📚 33392622📚32522674📚32975484 📚33163980📚33560374📚34050932 📚34851510📚34717820📚34385600 👩‍🏫Associate Professor of Psychiatry 🎓Washington University in St. Louis ⚕️School of Medicine 🌐 👩‍🔬📊🧬Research Interests: •neurodevelopmental disorders •schizophrenia •genetics •Wolfram syndrome /endoplasmic reticulum disorders •epidemiology •COVID-19 (drug repurposing) 💠💠💠💠Opinions are my own. 💠💠💠💠 ⚠️⚠️Educational content & other information given on Clubhouse is not medical advice. ⚠️⚠️ 🔆🔅🔆🔅🔆🔅🔆🔅🔆🔅🔆🔅🔆🔅🔆🔅 ♣️World Mental Health 🌏 🧠 ♣️2nd Time Around (2TA)💊♻️ (Drug repurposing club)